A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Impact of Major Vascular Complication Access Site Status on Mortality After Transfemoral Transcatheter Aortic Valve Replacement - Results From the FinnValve Registry
Tekijät: Laakso Teemu, Moriyama Noriaki, Raivio Peter, Dahlbacka Sebastian, Kinnunen Eeva-Maija, Juvonen Tatu, Valtola Antti, Husso Annastiina, Jalava Maina P., Ahvenvaara Tuomas, Tauriainen Tuomas, Piuhola Jarkko, Lahtinen Asta, Niemelä Matti, Mäkikallio Timo, Virtanen Marko, Maaranen Pasi, Eskola Markku, Savontaus Mikko, Airaksinen Juhani, Biancari Fausto, Laine Mika
Kustantaja: Japanese Circulation Society
Julkaisuvuosi: 2020
Journal: Circulation reports
Tietokannassa oleva lehden nimi: Circulation reports
Lehden akronyymi: Circ Rep
Vuosikerta: 2
Numero: 3
Aloitussivu: 182
Lopetussivu: 191
ISSN: 2434-0790
eISSN: 2434-0790
DOI: https://doi.org/10.1253/circrep.CR-20-0007
Verkko-osoite: https://www.jstage.jst.go.jp/article/circrep/2/3/2_CR-20-0007/_article
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/69071063
Background: The aim of this study was to investigate the impact of anatomical site status and major vascular complication (MVC) severity on the outcome of transfemoral transcatheter aortic valve replacement (TF-TAVR).
Methods and Results: The FinnValve registry enrolled consecutive TAVR patients from 2008 to 2017. MVC was divided into 2 groups: non-access site-related MVC (i.e., MVC in aorta, aortic valve annulus or left ventricle); and access site-related MVC (i.e., MVC in iliac or femoral arteries). Severity of access site-related MVC was measured as units of red blood cell (RBC) transfusion. Of 1,842 patients who underwent TF-TAVR, 174 had MVC (9.4%; non-access site related, n=29; access site related, n=145). Patients with MVC had a significantly higher 3-year mortality than those without MVC (40.8% vs. 24.3%; HR, 2.01; 95% CI: 1.16-3.62). Adjusted 3-year mortality risk was significantly increased in the non-access site-related MVC group (mortality, 77.8%; HR, 4.30; 95% CI: 2.63-7.02), but not in the access site-related MVC group (mortality, 32.6%; HR, 1.38; 95% CI: 0.86-2.15). In the access site-related MVC group, only those with RBC transfusion ≥4 units had a significantly increased 3-year mortality risk (mortality, 51.8%; HR, 2.18; 95% CI: 1.19-3.89).
Conclusions: In patients undergoing TF-TAVR, MVC was associated with an increased 3-year mortality risk, incrementally correlating with anatomical site and bleeding severity.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
